MedTrace Logo

A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma

NCT00857519 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-12-12

No results posted yet for this study

Summary

Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe. In recent years, there has been much interest in providing highly focused (focal) chemotherapy to a diseased organ including the liver, brain, and eye. With focused chemotherapy, the chemotherapy drugs are injected directly into the ophthalmic artery (the artery that supplies blood to the eye). A benefit of focal chemotherapy delivery is that it decreases the chance of toxicity to other organs such as bone marrow suppression (causing low blood counts) and the development of other cancers in the future.

Conditions

  • Retinoblastoma

Interventions

DRUG

Melphalan, Carboplatin

Intra-arterial chemotherapy.

Sponsors & Collaborators

  • Thomas Jefferson University

    collaborator OTHER

  • Wills Eye

    lead OTHER

Principal Investigators

  • Carol L Shields, MD · Oncology Service, Wills Eye Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-03-31
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857519 on ClinicalTrials.gov